Based upon the solid mechanistic framework provided by the mouse studies, the IMPACT (Improve Pregnancy in APS with Certolizumab Therapy) clinical trial is currently testing the hypothesis that adding blockade of TNF-α to the current standard of care will prevent imbalances in angiogenic factors and reduce incidence of preeclampsia in APS pregnancies (6). This evidence concerns the gene TNF and autoimmune polyendocrinopathy.